Non-alcoholic fatty liver disease: an overview.
Non-alcoholic fatty liver disease (NAFL) includes a spectrum of clinicopathological conditions with increasing prevalence in the developed world. Although steatosis alone seems to have a benign course, those patients with the diagnosis of non-alcoholic steatohepatitis (NASH) can have a progressive course. Additionally, there is now evolving, indirect evidence that some of the patients with cryptogenic cirrhosis may be the result of 'burned-out' NASH. Although NAFL and NASH are associated with insulin-resistance syndrome, some patients with NAFL may have no obvious risk factors. Despite preliminary data from a number of pilot studies, no established therapies can be offered to patients with NASH. Over the next few years, a number of exciting research projects dealing with the epidemiology as well as the pathogenesis of NAFL are expected to be completed. It is anticipated that, through a better understanding of NAFL, more effective treatment protocols can be developed targeting only those patients with NASH that are at the highest risk for progression to cirrhosis and liver failure.
Mulhall
Brian P
BP
Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, Falls Church, Virginia 22042, USA.
Ong
Janus P
JP
Younossi
Zobair M
ZM
D002908:Chronic Disease; D003937:Diagnosis, Differential; D018450:Disease Progression; D005234:Fatty Liver / Q000175:diagnosis* / Q000453:epidemiology / Q000628:therapy*; D006801:Humans; D008111:Liver Function Tests; D015995:Prevalence; D012307:Risk Factors